Dermal Priming in Enhancing Vaccine Immunogenicity | stella

Learn Find trials matched to me

Learn Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy For Researchers Data Labs ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Dermal Priming in Enhancing Vaccine Immunogenicity | stella

Back to ANCA Associated Vasculitis (AAV) trials

Recruiting

Plain-English translation of NCT07925996 on ClinicalTrials.gov ↗ · Source last updated November 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

Trial locations(1 site)

United Kingdom

Cambridge University Hospitals NHS Foundation Trust, Cambridge

Key details

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Collaborators

University of Cambridge

Enrollment target

~28 participants

Started

December 2025

Primary completion

June 2027

Age range

18 Years and older

Last updated on clinicaltrials.gov in November 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Rona Smith, MD

Cambridge University Hospitals NHS Foundation Trust

View full record on ClinicalTrials.gov

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.